血管新生相关因子在乙型肝炎相关肝细胞癌各临床分期中的表达分析

韩珍; 孙焕芹; 江娜; 刘宁; 徐杰; 孙坚萍; 张永宏

doi:10.3969/j.issn.1001-5256.2015.06.025

血管新生相关因子在乙型肝炎相关肝细胞癌各临床分期中的表达分析

DOI: 10.3969/j.issn.1001-5256.2015.06.025

首都医科大学附属北京佑安医院

基金项目:

北京市科技计划课题(D131100005313004;D131100005313005)；国家国际科技合作专项项目(2012DFA30850)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2088
- HTML全文浏览量: 31
- PDF下载量: 492
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Angiogenesis-related factors in various clinical stages of hepatitis B-related hepatocellular carcinoma

Research funding:

摘要

摘要:
目的研究血管新生相关因子在乙型肝炎相关肝细胞癌各临床分期中的表达情况及临床意义。方法选取2011-2013年于北京佑安医院就诊的乙型肝炎相关肝癌患者70例,按照肝癌分期标准将其分为肝癌早早期（n=18）、肝癌早期（n=17）、肝癌进展期（n=18）和肝癌晚期（n=17）,另选取18例健康人群作为对照。运用Luminex 200液相悬浮芯片系统检测血管内皮生长因子（VEGF）、血管内皮细胞生长因子受体（VEGFR）1和VEGFR-2、肝细胞生长因子（HGF）在乙型肝炎相关肝癌各临床分期中的表达情况。计量资料组间比较采用t检验。结果与对照组相比,在肝癌早早期,VEGF和HGF水平明显升高,差异均有统计学意义（t值分别为2.69、2.18,P值分别为0.008、0.002）;在肝癌早期,VEGF、VEGFR-1和HGF水平均明显升高,差异具有统计学意义（t值分别为1.73、2.03、2.54,P值分别为0.01、0.009、0.008）;在肝癌进展期,VEGF、VEGFR-1和HGF水平均明显升高,差异具有统计学意义（t值分别为1.64、4.38、4.02,P值分别为0.01、0.007、0...
- 癌,肝细胞 /
- 肝炎,乙型 /
- 血管内皮生长因子类 /
- 血管内皮生长因子受体1 /
- 血管内皮生长因子受体2 /
- 肝细胞生长因子
Abstract:
Objective To investigate the expression levels of angiogenesis- related factors in various clinical stages of hepatitis B- related hepatocellular carcinoma( HCC) and their clinical significance. Methods Seventy patients with hepatitis B- related HCC who were admitted to our hospital from 2011 to 2013 were enrolled as subjects and divided into four groups according to the HCC staging criteria: very early HCC group( n = 18),early HCC group( n = 17),advanced HCC group( n = 18),and end- stage HCC group( n = 17). Eighteen healthy volunteers were used as controls. The Luminex 200 liquid suspension array system was used to determine the expression levels of vascular endothelial growth factor( VEGF),vascular endothelial growth factor receptors( VEGFR- 1 and VEGFR- 2),and hepatocyte growth factor( HGF) in each clinical stage of hepatitis B- related HCC. Comparison of continuous data between two groups was made by t test. Results Compared with the control group,the very early HCC group had significantly higher levels of VEGF and HGF( t = 2. 69,P = 0. 008; t =2. 18,P = 0. 002). The early HCC group had significantly higher levels of VEGF,VEGFR- 1,and HGF than the control group( t = 1. 73,P = 0. 01; t = 2. 03,P = 0. 009; t = 2. 54,P = 0. 008). The levels of VEGF,VEGFR- 1,and HGF were significantly higher in the advanced HCC group than in the control group( t = 1. 64,P = 0. 01; t = 4. 38,P = 0. 007; t = 4. 02,P = 0. 005). In the end- stage HCC group,the levels of VEGF,VEGFR- 1,VEGFR- 2,and HGF were significantly higher than those in the control group( t = 4. 37,P =0. 007; t = 20. 24,P = 0. 009; t = 2. 21,P = 0. 01; t = 3. 06,P = 0. 003). Conclusion The levels of angiogenesis- related factors,VEGF and HGF,have already been substantially increased in the very early HCC,which induces a substantial upregulation of expression of VEGFR- 1 and VEGFR- 2 along with the progression of HCC.
- carcinoma,hepatocellular /
- hepatitis B /
- vascular endothelial growth factors /
- vascular endothelial growth factor receptor-1 /
- vascular endothelial growth factor receptor-2 /
- hepatocyte growth factor

HTML全文

参考文献(20)

[1]YANG L,YUE S,YANG L,et al.Sphingosine kinase/sphingosine1-phosphate(S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis[J].J Hepatol,2013,59(1):114-123.

[2]NAVARI M,ZARE M,JAVANMARDI M,et al.The diagnosis and treatment of brain metastases in EGFR mutant lung cancer[J].Immunopharmacol Immunotoxicol,2014,29:1-7.

[3]YASHIMA H,SHIMIZU K,ARAKI T,et al.EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer:a meta-analysis[J].Mol Clin Oncol,2014,2(5):714-718.

[4]STANIC K,ZWITTER M,HITIJ NT,et al.Lupeol induces apoptosis and inhibits invasion in gallbladder carcinoma GBC-SD cells by suppression of EGFR/MMP-9 signaling pathway[J].Radiol Oncol,2014,48(2):173-183.

[5]BRUIX J,SHERMAN M,LLOVET JM,et al.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver[J].J Hepatol,2001,35(3):421-430.

[6]European Association for Study of Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].Eur J Cancer,2012,48(5):599-641.

[7]FRACHON S,GOUYSSE G,DUMORTIER J,et al.Endothelial cell marker expression in dysplastic lesions of the liver:an immuno-histochemical study[J].J Hepatol,2001,34(6):850-857.

[8]CHUANG CH,LIU CH,LU TJ,et al.Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells[J].Toxicol Appl Pharmacol,2014,281(3):310-316.

[9]LIU Y,WANG CZ,LIU MH,et al.Research progress of VEGF/VEGFR signaling pathway in targeted therapy of liver cancer[J].Chin J Immunol,2013,29(1):97-101.(in Chinese)刘尧,王长振,刘明华,等.VEGF/VEGFR信号转导通路在肝癌靶向治疗中的研究进展[J].中国免疫学杂志,2013,29(1):97-101.

[10]UMEGUCHI H,SUEOKA-ARAGANE N,KOABYASHI N,et al.Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer[J].Oncol Rep,2015,33(1):391-396.

[11]NOUR S,MONNER M,BIKFALVI A.Recent developments in the regulation of the angiogenic switch by cellulars tress factors in tumors[J].Cancer Lett,2005,218(1):1-14.

[12]LIU Y,POON RT,LI Q,et al.Both an tiangiogen es is-and angio-genesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584[J].Cancer Res,2005,65(9):3691-3699.

[13]RASKOPF E,VOGT A,SAUERBRUCH T,et al.SiRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo[J].J Hepatol,2008,49(6):977-984.

[14]NAKAMURA K,ZEN Y,SATO Y,et al.Vascular endothelial growth factor,its receptor Flk-1,and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver[J].Hum Pathol,2007,38(10):1532-1546.

[15]KOH SA,KIM MK,LEE KH,et al.Rho GDI2 is associated with HGFmediated tumor invasion through VEGF in stomach cancer[J].Clin Exp Metastasis,2014,31(7):805-815.

[16]NAKADE J,TAKEUCHI S,NAKAGAWA T,et al.Triple inhibition of EGFR,Met,and VEGF suppresses regrowth of HGF-triggered,erlotinib-resistant lung cancer harboring an EGFR mutation[J].J Thorac Oncol,2014,9(6):775-783.

[17]CAMPBELL JS,HUGHES SD,GILBERTSON DG,et al.Plateletderived growth factor induces liver fibrosis,steatos is,and hepatocellular carcinoma[J].Proc Natl Acad Sci U S A,2005,102(9):3389-3394.

[18]YU D,SUN X,QIU Y,et al.Identification and clinical signifcance of mobilized endothelial progenitor cells in tumor vasculor genesis of hepatocellular carcinoma[J].Clin Cancer Res,2007,13(13):3814-3824.

[19]ABDEL-RAHMAN O.Vascular endothelial growth factor(VEGF)pathway and neuroendocrine neoplasms(NENs):prognostic and therapeutic considerations[J].Tumour Biol,2014,35(11):10615-10625.

[20]SHARMA PS,SHARMA R,TYAGI T,et al.VEGF/VEGFR pathway inhibitors as anti-angiogenic agents:present and future[J].Curr Cancer Drug Targets,2011,11(5):624-653.

施引文献

资源附件(0)

访问统计